Introduction
Over recent years, the search for outcome factors in patients with glioblastomas (GBM) has identified at least two candidates that have shown to be prognostic for progression-free and overall survival or predictive for response to a particular therapeutic modality, that is alkylating chemotherapy, in patients with high-grade gliomas. The
O6-methylguanine-DNA-methyltransferase (MGMT) gene encodes
MGMT, a protein with DNA repair activity, which removes alkyl groups from several residues, of which the O6-position of guanine might be most relevant for the action of an extensively used chemotherapeutic drug, temozolomide, by an irreversible transfer of the alkyl group to a cystein residue at it's active side [
1,
2]. The MGMT expression level and its activity varies widely between different tissues, cell types, and in particular, between different tumors [
3,
4]. It has been shown that glial brain tumors are characterized by a low expression of MGMT, however, the activity of MGMT is commonly increased in relation to surrounding normal tissue [
4,
5].
MGMT-activity is partly mediated through methylation of the
MGMT promoter region; this epigenetic mechanism contributing to a loss of MGMT-expression has been described by Esteller et al. [
6]. The epigenetically mediated silencing of the
MGMT gene in GBM has been shown to correlate with an increased survival: Some studies have shown significant correlation with MGMT-promoter methylation and outcome to alkylating chemotherapeutic substances such as temozolomide (TMZ) [
7]. Moreover, a correlation with outcome independently of treatment choice, i.e. chemotherapy or radiotherapy, has been postulated by some authors [
7,
8].
However, until now, most reports on the prognostic value of
MGMT-promoter methylation have answered this question in a retrospective manner. Additionally, several methods of
MGMT-promoter methylation confirmation have been used within the different studies, and comparative analyses have shown substantial heterogeneity in results after
MGMT-testing. In the literature, some authors have reported that
MGMT promoter methylation might not be correlated with outcome, either after treatment with radiotherapy, or with alkylating chemotherapeutic substances [
9,
10].
Only recently,
mutations of the IDH1 gene encoding cytosolic NADP+-dependent isocitrate dehydrogenase have been show to correlate with outcome in patients with malignant gliomas [
11,
12]. It has been proposed that
IDH1 mutations can be used to distinguish primary from secondary GBM, since
IDH1 mutations are associated with diffuse gliomas WHO Grade II and III as well as with secondary GBM, whereas primary GBM rarely show
IDH1 mutations.
We have treated a large group of patients with primary GBM with radiotherapy and chemotherapy with temozolomide. To determine the prognostic value of MGMT-promoter methylation and IDH1 mutational status, we analyzed both markers in a homogenous group of 160 patients with primary GBM treated with radiation and TMZ and correlated results with outcome.
Discussion
In the present analysis we evaluated the impact of
MGMT-promother methylation as well as IDH1-mutational status on outcome in 160 patients with GBM treated with radiation and temozolomide.
IDH1 mutations occur in approximately 60 - 80% of diffusely infiltrating gliomas of the WHO grades II and III and in secondary GBM but only in around 5% of primary GBM [
11,
18‐
22]. In our series we identified in 4 of 140 patients (3%)
IDH-1 mutations. Currently, it remains unclear if at least some of the patients with clinically defined primary GBM and
IDH1 mutations may actually have suffered from secondary GBM that rapidly progressed from less malignant precursor lesions that escaped diagnosis [
23]. In summary,
IDH1 is a sufficient marker that allows a better separation of primary GBM from other malignant astrocytomas than any other marker and will help to define more accurately this tumor entity in upcoming studies. The low number of primary GBM exhibiting
IDH1 mutations in our series indicates that our sample set consists indeed predominately of these tumors.
IDH1 mutations in GBM were found in general in younger patients and were associated with a better prognosis [
22‐
24]. This has been confirmed in the present study, showing that
IDH1 mutational status, although only positive in few patients, is associated with younger age and lower survival times than in the group of patients with wildtype
IDH1. Therefore, the pattern of IDH1 mutations confirm that the present group of 160 patients with GBM is a very homogeneous group with respect to histological clasification.
In contrast to most studies,
MGMT-promoter methylation was not associated with an increase in OS or PFS; both endpoints were comparable in patients with active MGMT or with MGMT silencing. The only subgroup of patients showing a significant impact of
MGMT-promoter methylation on survival were patients older than 60 years, where
MGMT-promoter methylation was associated with an increase in OS. This is in contrary to the results published by Stupp and colleagues [
7,
15]. Therefore, the strong impact on
MGMT-promoter methylation might not hold true for all age groups of patients with GBM. The EORTC 26981/22981/NCIC CE.3 study by Stupp et al. determining the role for chemoradiation with temozolomide has shown
MGMT-promoter methylation to be strongly associated with an improved outcome [
7,
15]. In contrast, other studies in anaplastic gliomas have shown that
MGMT-methylation status dose not only influence outcome after alkylkating chemotherapies but also radiotherapy and may therefore be prognostic rather than predictive. This is reported by numerous other studies [
8]. However, controversial results have also been published in groups of GBM patients, in which MGMT-status is not associated with differences in outcome: Costa et al. reports on 90 GBM-patients treated with temozolomide-based chemoradiation where
MGMT promoter methylation was not associated with increased outcome [
10]. Park et al. published 48 patients treated with alkylating chemotherapy and could not confirm a significant impact of methylation status of
MGMT gene promoter [
9]. Many arguments may be brought forward to explain these differing clinical data, including the various methods of measurement of MGMT-activity sometimes showing discrepant results, differences between frozen or paraffin embedded tissues. Additionally, when analyzing different chemotherapeutic combinations, substances such as cisplatinum might inactivate or attenuate MGMT-status thus influencing the clinical outcome when combined with alkylating chemotherapies. An important differential explanation is the variation of the treatment in our cohort as compared to the published data [
7,
16,
17,
25,
26] with a lower exposure of our patients to alkylating chemotherapy both in the concomitant phase (50 mg in 78% and 75 mg in only 22%) as well as in the maintenance phase (no adjuvant treatment in 79% and a mean of 6 cycles in 21% of patients). However, inspite of this difference, outcome between the two dosing groups of temozolomide was identical, therefore counteracting this argument.
In conclusion, controversial results exist on the impact of MGMT-promoter methylation status in patients with GBM, and further studies will hopefully further clarify these differences. At this time, in spite of the strong evidence for a high impact of MGMT-promoter methylation, differentiating treatment strategies based on MGMT-promoter methylation status should therefore be applied within the framework of clinical studies only.
Authors' contributions
SC, SR, WW and JD treated the patients and collected the cllinical data. SC and JD performed the clinical analysis of the dataset. CH and AVD performed the histopathological and molecular analysis. SC, JD, CH and AA analyszed the prognostic relevance of the molecular data. SC and CH wrote the mansucript. JD, AVD, WW, SR and AA helped with manuscript finalization and discussion.